fda semaglutide warning november 2025 Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly Higher-Dose Semaglutide Approved Under New

Farr OM, Li Cshan, Mantzoros R

doi: 10.1111/sji.12998 14

On the other hand, Wegovy is started on a lower dose of 0.25mg subcutaneously once weekly and this dosage increases every four weeks by an additional .25mg until reaching its maximum dose of 2.4mg/week for chronic weight management in adult patients who are overweight or obese

The neuropsychiatry of vitamin B12 deficiency in elderly patients

Obesity rates are also climbing globally, with the World Health Organization (WHO) reporting over one billion individuals affected in 2022

Some are confused by online claims about GLP-1, GLP-3, semaglutide, tirzepatide, peptides, and hormone-based weight loss treatments